| FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE<br>INFORMATION DISCLOSURE STATEMENT BY APPLICANT<br>(USE SEVERAL SHEETS IF NECESSARY) | ATTY. DOCKET NO.<br>202.2D6 | APPLICATION NO.<br>10/741,929 |
|---|---|---|
| | APPLICANT<br>Clarence N. Ahlem, et al | |
| | FILING DATE<br>December 19, 2003 | GROUP<br>1617 |



**U.S. PATENT DOCUMENTS**

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE (IF APPROPRIATE) |
|---|---|---|---|---|---|---|---|
| BB | | 2,878,267 | 05/17/59 | Szpilfogel et al | | | |
| | | 5,567,695 | 10/22/96 | Labrie | | | |
| | | 5,763,433 | 06/09/98 | Morfin | | | |
| | | 5,776,923 | 07/07/98 | Labrie | | | |
| | | 5,837,269 | 11/17/98 | Daynes et al. | | | |
| BB | | 6,077,873 | 06/20/00 | Loozen | | | 2/19/98 |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |

**U.S. PATENT APPLICATION PUBLICATIONS**

| EXAMINER INITIAL | | DOCUMENT PUBLICATION NUMBER | NAME AND PORTIONS OF DOCUMENT | CLASS | SUBCLASS | FILING DATE (IF APPROPRIATE) |
|---|---|---|---|---|---|---|
| BB | | US 2005/0075321 A1 | Ahlem et al., first page and pages 102-107 (claims) | | | |
| | | US 2004/0043973 A1 | Ahlem et al., first page and pages 99-101 (claims) | | | |
| BB | | US 2003/0119800 A1 | Manolagas et al., entire document | | | |

**FOREIGN PATENT DOCUMENTS**

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION YES | TRANSLATION NO |
|---|---|---|---|---|---|---|---|---|
| BB | | EP 0 429 187 B1 | 05/01/94 | Europe | | | | |
| | | EP 0 289 327 A | 11/02/88 | Europe | | | | |
| | | EP 01 133 995 A2 | 08/02/83 | Europe | | | | |
| BB | | DE 38 12 595 C2 | 10/27/88 | Germany | | | X | |

| EXAMINER | DATE CONSIDERED |
|---|---|
| Badio | 9/13/05 / 1/10/06 |

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

| FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | ATTY. DOCKET NO. 202.2D6 | APPLICATION NO. 10/741,929 |
|---|---|---|
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | APPLICANT Clarence N. Ahlem, et al | |
| (USE SEVERAL SHEETS IF NECESSARY) | FILING DATE December 19, 2003 | GROUP 1617 |

| EXAMINER INITIAL | | OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.) |
|---|---|---|
| BB | | Araghi-Niknam et al., Modulation of immune dysfunction during murine leukaemia retrovirus infection of old mice by dehyroepiandrosterone sulphate (DHEAS), *Immunology* 90:344-349 (1997) |
| | | Araghi-Niknam et al., Cytokine Dysregulation and Increased Oxidation IS Prevented by Dehydroepiandrosterone in Mice Infeced with Murine Leukemia Retrovirus, *Proc. Soc. Exp. Biol. Med.* 216(3):386-391 (1997) |
| | | B. F. Bebo et al., Androgens alter the cytokine profile and reduce encephalitogenicity of myelin-reactive T cells, *J. Immunol.* 162:35-40 1999 |
| | | Henderson et al., Dehydroepiandrosterone and 16α-bromoepiandrosterone: Inhibitors of Epstein-Barr virus induced transformation of human lymphocytes, *Carcinogenesis*, 2(7), pp. 683-686 1981 |
| | | Hernandez-Pando et al., The effects of androstenediol and dehydroepiandrosterone on the course and cytokine profile of tuberculosis in BALB/c mice, *Immunology* 95(2):234-241 1998 |
| | | P. Inserra et al., Modulation of cytokine production by dehydroepiandrosterone (DHEA) plus melatonin (MLT) supplementation of old mice, *Proc. Soc. Exp. Biol. Med.* 218:76-82 1998 |
| | | Kang et al., Dehydroepiandrosterone and β-endorphin enhance IL-12 gene expression, *Taehan Miseengmulhak Hoechi (J. Korean Soc. Microbiology)* 31(4):399-404 (1996) (translation from Korean) |
| | | Kang et al, Dehydroepiandrosterone and β-endorphin enhance IL-12 gene expression, *Chem Abstracts 2-Mammalian Hormones* 126(9) pp. 99 (Abstract 113406a) |
| | | Kousteni S, et al. Reversal of bone loss in mice by nongenotropic signaling of sex steroids, *Science* 298:843-846 2002 |
| | | Manz et al., Methyl 17α-Carboxyester Derivatives of Natural and Synthetic Glucocorticoids: Correlation Between Receptor Binding and Inhibition of in vitro Phytohaemagglutinin-Induced Lymphocyte Blastogenesis, *J. Clin. Chem. Clin. Biochem.* 21(2):69-75 (1983) |
| | | Sigg et al., Methyl 3α-acetoxyetien-(8:9 or 8:14)-ate, Preliminary Communication, Helvetica Chimica Acta, 39:1507-1525 1956 (translation from German) |
| | | Xia P, et al. Anti-Aids agents. Part 36: 1 17-carboxylated steroids as potential anti-HIV agents, *BIOORG Med. Chem* 7(9), pp. 1907-1911 (Sep 1999) |
| | | Yang et al., Inhibition of HIV-1 Latency Reactivation by Dehydroepiandrosterone (DHEA) and an Analog of DHEA, *Aids Research and Human Retroviruses* 9(8):747-754 (1993) |
| BB | | Z. Zhang et al., Prevention if immune dysfunction and vitamin E loss by dehydroepiandrosterone and melatonin supplementation during murine retrovirus infection, *Immunology* 96:291-297 1999 |

| EXAMINER Bada | DATE CONSIDERED 9/13/05 |
|---|---|

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

| FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | ATTY. DOCKET NO. 202.2D6 | APPLICATION NO. 10/741,929 |
|---|---|---|
| SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY) | APPLICANT Clarence N. Ahlem, et al | |
| | FILING DATE December 19, 2003 | GROUP 1617 |



**U.S. PATENT DOCUMENTS**

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE (IF APPROPRIATE) |
|---|---|---|---|---|---|---|---|
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |

**U.S. PATENT APPLICATION PUBLICATIONS**

| EXAMINER INITIAL | | DOCUMENT PUBLICATION NUMBER | NAME | CLASS | SUBCLASS | FILING DATE (IF APPROPRIATE) |
|---|---|---|---|---|---|---|
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

**FOREIGN PATENT DOCUMENTS**

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION YES | TRANSLATION NO |
|---|---|---|---|---|---|---|---|---|
| BB | | H6-279488 | 10-04-94 | Japan | --- | --- | X | |
| | | | | | | | | |
| | | | | | | | | |

| EXAMINER INITIAL | OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.) |
|---|---|
| BB | Bruder, S. P., et al., Mesenchymal stem cells in bone development, bone repair, and skeletal regeneration therapy, *J Cell Biochem*, 56(3), pp. 283-94, 1994 |
| | Chen, Z.et al., Estrogen receptor alpha mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen. *J. Clin. Invest.* 103, pp. 401-406, 1999 |
| | Fink, B. E. et al., Novel structural templates for estrogen-receptor ligands and Prospects for Combinatorial Synthesis of Estrogens. *Chem. Biol.*, 6, pp. 205-219,1999 |
| | Gao, H. et al., Comparative QSAR analysis of estrogen receptor ligands, *Chem. Rev.*, 99, pp. 723-744, 1999 |
| | Grundy, J., Artificial Estrogens. The Technical College, Acton, London, W.S., England, pp.281-416, May 1956 |
| BB | Jilka RL, et al., Increased osteoclast development after estrogen loss: mediation by interlekin-6, *Science* 257, pp. 88-91, 1992 |

| EXAMINER Babic | DATE CONSIDERED 9/13/05 |
|---|---|

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

| FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | ATTY. DOCKET NO. 202.2D6 | APPLICATION NO. 10/741,929 |
|---|---|---|
| SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT | APPLICANT Clarence N. Ahlem, et al | |
| (USE SEVERAL SHEETS IF NECESSARY) | FILING DATE December 19, 2003 | GROUP 1617 |

| EXAMINER INITIAL | | OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.) |
|---|---|---|
| BB | | Jilka, R.L. et al., Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone, *Journal of Clinical Investigation*, 104(4), pp 439-446 August 1999. |
| | | Khosla, S. et al., Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: A key role for bioavailable estrogen. *J. Clin. Endocrinol. Metab.* 83, pp. 2266-2274, 1998 |
| | | Lea, C.K. et al., Androstenedione treatment reduces loss of cancellous bone volume in ovariectomized rats in a dose-responsive manner and the effect is not mediated by estrogen, *J. Endocrinol.*, 156, pp. 331-339, 1988 |
| | | Ojasoo, T. and Raynaud, J. P. Unique steroid congeners and receptors studies, *Cancer Res.*, 38, pp. 4186-4198, 1978 |
| | | Oursler M. J., Estrogen regulation of gene expression in osteoblasts and osteoclasts *Critical Review in Eucaryotic Gene Expression*, 8:125-140 1998 |
| | | Picherit, C. et al., Dihydrotesterone prevents glucocorticoid-negative effects on fetal rat metatarsal bone *in vitro*, *Biol. Neonate*, 77:181-190 2000 |
| | | Pietras, R.J. and C.M.Szego. Specific binding sites for oestrogen at the outer surfaces of isolated endometrial cells. *Nature*, 265, pp.69-72, 1977 |
| | | Plotkin, L.I., et al., Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin, *J. Clin. Invest.* 104(10):1363-1374 November 1999. |
| | | Pomper, M. G., et al., 11β-Methoxy-, 11β-ethyl- and 17α-ethynyl-substituted 16α-fluoroestradiols: Receptor-based imaging agents with enhanced uptake efficiency and selectivity. *J. Med. Chem.*, 33, pp. 3143-3155, 1990 |
| | | Riggs, B, et al. Short- and long-term effects of estrogen and synthetic anabolic hormone in postmenopausal osteoporosis, *J. Clin. Invest.*, 51, pp.1659-1663, 1972 |
| | | Santoro, N.F., et al, Therapeutic controversy: Hormone replacement therapy-where are we going? *J. Clin. Endocrinol. Metab.* 84, pp.1798-1812, 1999 |
| | | Scheven B.A., et al, Dehydroepiandrosteone (DHEA) and DHEA-S interact with 1,25-dihydroxyvitamin $D_3$ ($1,25(OH)_2D_3$) to stimulate human osteoblastic cell differentiation Life Sciences, 62, pp. 59-68, 1988 |
| BB | | Solmssen, U. V., Synthetic estrogens and the relation between their structure and their activity. *Chem. Res.*, 37, pp. 481-598, 1945 |
| | | Tedesco, R., Katzenellenbogen, J. A. and Napolitano, E. 7α,11β-Disubstituted estrogens: Probes for the shape of the ligand binding pocket in the estrogen receptor. Bioorg. Med. Chem. Lett., 7, 2919-2924 1997 Copy needed |
| | | Tobias, J.H., et al., 5α-dihydrotestosterone partially restores cancellous bone volume in osteopenic ovariectomized rats, *Am. J. Physiol. Endocrinol. Metab.* 267, pp. E853-E859, 1994. Copy needed |
| BB | | Watts, N. B., Clinical utility of biochemical markers of bone remodeling, *Clin. Chem.*, 45, pp. 1359-1368, 1999 |
| | | Weinstein R.S. et al., Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids *J. Clin.Invest.* 102, pp. 274-282, 1998 |
| BB | | Weinstein RS et al., The effects of androgen deficiency on murine bone remodeling and bone mineral density are mediated via cells of the osteoblastic lineage, *Endocrinology* 138, pp. 4013-4021, 1997 |

| EXAMINER | DATE CONSIDERED 9/13/05 |
|---|---|

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

| FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE<br>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT<br>(USE SEVERAL SHEETS IF NECESSARY) | ATTY. DOCKET NO.<br>202.2D6 | APPLICATION NO.<br>10/741,929 |
|---|---|---|
| | APPLICANT<br>Clarence N. Ahlem, et al | |
| | FILING DATE<br>December 19, 2003 | GROUP<br>1617 |



**U.S. PATENT DOCUMENTS**

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE (IF APPROPRIATE) |
|---|---|---|---|---|---|---|---|
| BB | 1 | 2,843,608 | 07-15-58 | Colton | | | |
| | 2 | 2,843,609 | 07-15-58 | Colton | | | |
| | 3 | 4,069,321 | 01-17-78 | Jones et al. | | | |
| | 4 | 5,011,678 | 04-30-91 | Wang et al. | | | |
| | 5 | 5,116,828 | 05-26-92 | Miura et al. | | | |
| | 6 | 5,162,312 | 11-10-92 | Kasch et al. | | | |
| | 7 | 5,183,815 | 02-02-93 | Saari et al. | | | |
| | 8 | 5,565,444 | 10-15-96 | Mitzushima et al. | | | |
| | 9 | 5,795,883 | 08-18-83 | Hesch et al. | | | |
| | 10 | 5,817,816 | 10-06-98 | Harimaya et al. | | | |
| | 11 | 5,837,700 | 11-17-98 | Labrie | | | |
| | 12 | 5,843,934 | 12-01-98 | Simpkins | | | |
| | 13 | 5,846,960 | 12-08-98 | Labrie | | | |
| | 14 | 5,880,117 | 03-03-99 | Arnold | | | |
| | 15 | 6,011,026 | 01-04-00 | Bouali et al. | | | |
| | 16 | 6,011,027 | 01-04-00 | Arnold | | | |
| | 17 | 6,313,180 B1 | 11-06-01 | Loozen | | | |
| BB | 18 | 6,667,299 B1 | 12-23-03 | Ahlem et al. | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |

| EXAMINER | DATE CONSIDERED |
|---|---|
| Dadso | 9/13/05 |

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

| FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE<br>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT<br>(USE SEVERAL SHEETS IF NECESSARY) | ATTY. DOCKET NO.<br>202.2D6 | APPLICATION NO.<br>10/741,929 |
|---|---|---|
| | APPLICANT<br>Clarence N. Ahlem, et al | |
| | FILING DATE<br>December 19, 2003 | GROUP<br>1617 |



**U.S. PATENT APPLICATION PUBLICATIONS**

| EXAMINER INITIAL | | DOCUMENT PUBLICATION NUMBER | NAME | CLASS | SUBCLASS | FILING DATE (IF APPROPRIATE) |
|---|---|---|---|---|---|---|
| BB | 19 | US 2005/0101581 A1 | Ahlem et al. | | | |
| | 20 | US 2005/0026223 A1 | Manolagas et al. | | | |
| | 21 | US 2004/0248078 A1 | Manolagas et al. | | | |
| | 22 | US 2004/0220114 A1 | Ahlem et al. | | | |
| | 23 | US 2004/0224884 A1 | Manolagas et al. | | | |
| | 24 | US 2004/0138187 A1 | Ahlem et al. | | | |
| | 25 | US 2004/0157812 A1 | Labrie | | | |
| | 26 | US 2004/0116359 A1 | Ahlem et al. | | | |
| | 27 | US 2004/0097406 A1 | Ahlem et al. | | | |
| | 28 | US 2003/0225046 A1 | Liao et al. | | | |
| | 29 | US 2003/0083231 A1 | Ahlem et al. | | | |
| | 30 | US 2003/0060425 A1 | Ahlem et al. | | | |
| BB | 31 | US 2002/0187970 A1 | Labrie | | | |

**FOREIGN PATENT DOCUMENTS**

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | YES | NO |
| BB | 32 | WO 00/20007 | 04-13-00 | PCT | | | | |
| | 33 | WO 99/61044 | 12-02-99 | PCT | | | | |
| | 34 | WO 99/63973 | 12-16-99 | PCT | | | | |
| | 35 | WO 98/56386 | 12-17-98 | PCT | | | | |
| BB | 36 | WO 93/10141 | 05-27-93 | PCT | | | | |

| EXAMINER Badio | DATE CONSIDERED 9/13/05 / 1/16/06 |
|---|---|

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

| FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | ATTY. DOCKET NO. 202.2D6 | APPLICATION NO. 10/741,929 |
|---|---|---|
| SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY) | APPLICANT Clarence N. Ahlem, et al | |
| | FILING DATE December 19, 2003 | GROUP 1617 |



| EXAMINER INITIAL | | OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE) |
|---|---|---|
| BB | 37 | Karsenty, The genetic transformation of bone biology, *Genes & Development*, 13:3037-3051 1999 |
| BB | 38 | Slemenda et al., Sex steroids, bone mass and bone losss, *J. Clinical Invest.*, 97:14-21 1996 |
| | | |

| EXAMINER | DATE CONSIDERED |
|---|---|
| Baba | 9/13/05 |

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

| FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | ATTY. DOCKET NO. 202.2D6 | APPLICATION NO. 10/741,929 |
|---|---|---|
| SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY) | APPLICANT Clarence N. Ahlem, et al | |
| | FILING DATE December 19, 2003 | GROUP 1617 |



**U.S. PATENT DOCUMENTS**

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE (IF APPROPRIATE) |
|---|---|---|---|---|---|---|---|
| BD | | 4,096,254 | 06-20-78 | Benson et al | — | — | |
| | | | | | | | |

**U.S. PATENT APPLICATION PUBLICATIONS**

| EXAMINER INITIAL | | DOCUMENT PUBLICATION NUMBER | NAME | CLASS | SUBCLASS | FILING DATE (IF APPROPRIATE) |
|---|---|---|---|---|---|---|
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

**FOREIGN PATENT DOCUMENTS**

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION YES | TRANSLATION NO |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |

| EXAMINER INITIAL | | OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.) |
|---|---|---|
| BD | | Cunningham, G.R. et al, Steroid structural requirements for high affinity binding to human sex steroid binding protein (SBP), *Steroids* 38(3):243-262 1981 |
| | | Ederveen, A.G., et al, Tibolone, a steroid with a tissue-specific hormonal profile, completely prevents ovariectomy-induced bone loss in sexually mature rats, *J Bone Miner Res*,, 14 (11):1963-70 1999 |
| | | Tedesco, R., Katzenellenbogen, J. A. and Napolitano, E. 7α,11β-Disubstituted estrogens: Probes for the shape of the ligand binding pocket in the estrogen receptor. Bioorg. Med. Chem. Lett., 7:2919-2924 1997 |
| BD | | Tobias, J.H., et al. , 5α-dihydrotestosterone partially restores cancellous bone volume in osteopenic ovariectomized rats, *Am. J. Physiol. Endocrinol. Metab.* 267:E853-E859 1994 |
| | | |
| | | |

| EXAMINER Badio | DATE CONSIDERED 1/10/06 |
|---|---|

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.